Publication relating to transparency notifications Nyxoah (NASDAQ/EBR: NYXH) disclosed a transparency notification dated March 19, 2026 after Robelga SRL crossed the 3% threshold on December 30, 2025. The combined holding of Robert Taub and related undertakings equals 4,360,800 voting rights (10.14%) of 43,026,460 total voting rights.The notification lists 4,310,800 voting rights linked to securities and 50,000 equivalent instruments (warrants expiring 08/06/2027 and 14/06/2028). Ownership chain: Robelga SRL 100% owned by BMI Estate; usufruct by Robert Taub; bare ownership by his children.

#NYXH Publication relating to transparency notifications

www.stocktitan.net/news/NYXH/publication-re...

#NYXH #9525e72e-f21a-4c82-a086-d1f5d20a525b #earningscall-transcripts

Origin | Interest | Match

Sleep apnea device maker says U.S. launch trained 145 surgeons 57 U.S. accounts were activated by year-end, with Medicare and commercial reimbursement in place. Nyxoah sees Q1 and Q2 sales up 25%.

#NYXH Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

www.stocktitan.net/news/NYXH/nyxoah-reports...

Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 Mont-Saint-Guibert, Belgium – March 5 2026, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive

#NYXH Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

www.stocktitan.net/news/NYXH/nyxoah-to-rele...

Publication relating to transparency notifications Nyxoah (NASDAQ/EBR: NYXH) received a transparency notification dated February 26, 2026, reporting that Robert Taub and related person BMI Estate now hold 4,360,800 voting rights (9.99%) of total voting rights (43,662,403) as of February 20, 2026.The holding comprises 4,310,800 linked securities and 50,000 warrants exercisable through 2028. Ownership passes via BMI Estate and Robelga SRL with described usufruct and bare ownership arrangements.

#NYXH Publication relating to transparency notifications

www.stocktitan.net/news/NYXH/publication-re...

Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth Nyxoah (Nasdaq: NYXH) announced an investment to expand its Belgian manufacturing capacity on January 21, 2026. The company signed an agreement with LégiaPark to create a nearly 2,000 square meters facility in Wallonia that includes a scalable, state-of-the-art cleanroom developed with ABN Cleanroom Technology. The expansion is intended to support growing demand in the United States and international markets, strengthen manufacturing readiness, foster local job creation, and, the company said, help improve its gross margin profile.

#NYXH Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth

www.stocktitan.net/news/NYXH/nyxoah-invests...

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026 Nyxoah (NASDAQ: NYXH) reported preliminary unaudited results for Q4 and full-year 2025 and gave Q1 2026 revenue guidance. Q4 2025 gross revenue is ~€6.3M and net revenue ~€5.7M, up ~348% versus Q4 2024. FY2025 gross revenue is ~€11.0M and net revenue ~€10.0M, up ~122% versus FY2024. Deferred revenue related to disposable patches is ~€0.6M in Q4 and ~€1.0M for FY2025. As of Dec 31, 2025 the company trained 145 surgeons, activated 57 U.S. accounts, and held ~€47.9M in cash, cash equivalents and financial assets. Nyxoah expects U.S. net revenue Q1 2026 to grow ~25% sequentially and international revenue to follow seasonal patterns. Results are preliminary and subject to revision ahead of the 2025 Form 20-F filing.

#NYXH Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026

www.stocktitan.net/news/NYXH/nyxoah-announc...

Publication relating to transparency notification REGULATED INFORMATION Publication relating to transparency notification Mont-Saint-Guibert (Belgium), January 12, 2026 , 7:00 am CET / 1:00 am ET – In accordance with article 14 of the Law of May 2, 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces

#NYXH Publication relating to transparency notification

www.stocktitan.net/news/NYXH/publication-re...

Nyxoah Announces Issuance of First Tranche of Convertible Bonds Nyxoah Announces Issuance of First Tranche of Convertible Bonds Mont-Saint-Guibert, Belgium – December 19, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“ Nyxoah ” or the “ Company ”), a medical technology company focused on the development and commercialization of

#NYXH Nyxoah Announces Issuance of First Tranche of Convertible Bonds

www.stocktitan.net/news/NYXH/nyxoah-announc...

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands First Genio implants successfully performed at OLVG West and Zuyderland hospitals Mont-Saint-Guibert, Belgium – December 17, 2025, 7:05am CET / 1:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or

#NYXH Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Netherlands

www.stocktitan.net/news/NYXH/nyxoah-announc...

Publication relating to transparency notifications Nyxoah (NASDAQ/Euronext: NYXH) received two transparency notifications from Robert Taub and related BMI Estate disclosing changes in voting rights on November 27 and December 2, 2025.As of November 20, 2025 the holding totaled 4,290,800 voting rights (9.97%). As of December 1, 2025 the holding rose to 4,360,800 voting rights (10.14%), consisting of 4,310,800 linked securities and 50,000 warrants. The notifications identify controlled undertakings including Robelga SRL and describe ownership chains.

#NYXH Publication relating to transparency notifications

www.stocktitan.net/news/NYXH/publication-re...

Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule 01 Communique (TSXV: ONE / OTCQB: OONEF) and Turnium Technology Group (TSXV: TTGI) signed a strategic partnership agreement effective August 31, 2025 to deliver IronCAP X™ post-quantum cryptography (PQC) email service to enterprise customers.The agreement will let TTGI offer IronCAP X via its Technology-as-a-Service network to industries like finance, healthcare, and government. IronCAP X is an end-to-end email and file encryption system built on NIST-approved PQC (FIPS-203 and FIPS-204) that integrates with Microsoft Office Outlook and offers digital signing and encryption with patent protection.

#NYXH Nyxoah’s Genio® Therapy Receives Significant 2026 Medicare Reimbursement Increases Under Final CMS Rule

www.stocktitan.net/news/NYXH/nyxoah-s-genio...

Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Nyxoah (Nasdaq: NYXH) announced financing commitments totaling up to U.S. $77 million to accelerate U.S. commercialization of the Genio system. The package includes a €22 million private placement (5,481,678 shares at €4.00), a U.S. $5.6 million registered direct offering (1,215,964 shares at $4.6304), and a convertible bond facility of up to €45 million (first tranche €22.5 million).Closings are expected around Nov 17–18, 2025 for equity and Dec 2025 for the first bond tranche. Net proceeds will fund U.S. commercialization, clinical research, R&D, manufacturability and general corporate purposes.

#NYXH Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio

www.stocktitan.net/news/NYXH/nyxoah-secures...

Nyxoah Reports Third Quarter 2025 Financial and Operating Results REGULATED INFORMATION Nyxoah Reports Third Quarter 2025 Financial and Operating Results US launch off to a strong start. First commercial Genio implants completed with widespread payer coverage drives initial revenue. Mont-Saint-Guibert, Belgium – November 13, 2025, 10:10pm CET / 4:10 pm ET –

#NYXH Nyxoah Reports Third Quarter 2025 Financial and Operating Results

www.stocktitan.net/news/NYXH/nyxoah-reports...

Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System Nyxoah (NASDAQ: NYXH) announced on October 6, 2025 that the first U.S. commercial patients have been implanted with the Genio® system following FDA approval. The PR states the company has trained surgeons, secured Value Analysis Committee approvals, and achieved payor coverage including CMS. Dr. Andrew T. Huang performed the initial U.S. commercial implants at Townsen Memorial Health System in Houston, completing five implants in one week. Nyxoah says it will track surgeon training, VAC submissions, prior authorizations, and accounts opened as leading indicators of future revenue growth.

#NYXH Nyxoah Announces First U.S. Commercial Patients Implanted with Genio® System

www.stocktitan.net/news/NYXH/nyxoah-announc...

Publication relating to transparency notifications Nyxoah (NASDAQ: NYXH) published a transparency notification on October 3, 2025 reporting a holding change by Vestal Point Capital.Per the notification dated September 30, 2025, Vestal Point Capital, LP now holds 1,113,575 voting rights, representing 2.97% of total voting rights (denominator: 37,544,782) as of September 24, 2025. The filing notes a downward crossing of the 3% threshold. Vestal Point Capital, LLC is the GP controlled by Ryan Wilder; Vestal Point Capital, LP acts as investment manager and may exercise voting rights at its discretion.

#NYXH Publication relating to transparency notifications

www.stocktitan.net/news/NYXH/publication-re...

Revolutionary Sleep Apnea Treatment: Nyxoah's Genio System Expands Across Middle East Healthcare Hubs Medical tech company Nyxoah expands Genio treatment for OSA to Dubai, Kuwait, and Abu Dhabi following first implant. Leadless bilateral nerve stimulation system targets CPAP-intolerant patients.

#NYXH Nyxoah Provides an Update on Expanded Middle East Presence

www.stocktitan.net/news/NYXH/nyxoah-provide...

Sleep Apnea Tech Battle: Nyxoah Takes Inspire Medical to Court Over 3 Key Patents in OSA Treatment Nyxoah alleges Inspire IV and V devices infringe three US patents for OSA treatment. Lawsuit seeks injunctive relief and damages, defending Genio system's bilateral stimulation technology.

#NYXH Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.

www.stocktitan.net/news/NYXH/nyxoah-files-p...

5.63M Shares: Cochlear Investments Updates Ownership Position in Sleep Apnea Innovator Nyxoah Below 15% Nyxoah received transparency notification from Cochlear Limited regarding subsidiary Cochlear Investments' passive threshold crossing, now holding 5.63M voting rights (14.999%) as of Aug 29, 2025.

#NYXH Publication relating to transparency notifications

www.stocktitan.net/news/NYXH/publication-re...

Nyxoah Reports Second Quarter Financial and Operating Results Nyxoah (NASDAQ:NYXH) has achieved a significant milestone with FDA approval of its Genio system, the first and only bilateral hypoglossal neurostimulation therapy for Obstructive Sleep Apnea (OSA) in the U.S. market. The company has initiated its commercial launch with strong Q2 2025 results, reporting revenue of €1.3 million, a 74% year-over-year increase.The Genio system's approval was supported by the DREAM pivotal trial data, demonstrating 66.6% median AHI reduction in supine position and 71.0% reduction in non-supine position. The company's cash position stands at €43.0 million as of June 30, 2025, with an additional €27.5 million available through a term debt facility.Operating loss increased to €19.9 million in Q2 2025, primarily due to expanded commercialization efforts and R&D activities.

#NYXH Nyxoah Reports Second Quarter Financial and Operating Results

www.stocktitan.net/news/NYXH/nyxoah-reports...

Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Nyxoah (NASDAQ: NYXH), a medical technology company focused on Obstructive Sleep Apnea (OSA) treatment, has announced preliminary Q2 2025 results. The company achieved revenue of €1.3 million, marking a 73% year-over-year increase. Operating expenses rose 50% to €20.7 million.Key developments include FDA approval of the Genio® system for moderate to severe OSA patients with AHI between 15 and 65. The company maintains €43.0 million in cash and equivalents, with access to an additional €27.5 million in debt facility. Nyxoah plans to conclude ACCCESS trial enrollment early while maintaining the study's co-primary endpoints. The company faces a patent infringement lawsuit from Inspire Medical Systems and is reorganizing its R&D operations from Israel to the U.S. and Belgium.

#NYXH Nyxoah Announces Preliminary Results for the Second Quarter of 2025

www.stocktitan.net/news/NYXH/nyxoah-announc...

Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea Nyxoah (NASDAQ: NYXH) has received FDA approval for its Genio® system, a breakthrough treatment for moderate to severe Obstructive Sleep Apnea (OSA). The approval covers patients with an Apnea-Hypopnea Index (AHI) between 15 and 65.The Genio system represents a novel approach to hypoglossal nerve stimulation, featuring bilateral stimulation and a unique leadless design that is MRI compatible. The system's efficacy was demonstrated in the DREAM pivotal trial, achieving a 63.5% AHI responder rate and an impressive 70.8% median AHI reduction.Notably, the system showed consistent effectiveness across all sleeping positions, with a 66.6% median AHI reduction in supine position and 71.0% reduction in non-supine position. The company has officially launched its U.S. commercialization efforts.

#NYXH Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea

www.stocktitan.net/news/NYXH/nyxoah-receive...

Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine Nyxoah (NASDAQ:NYXH) announced the publication of its DREAM pivotal study data in the Journal of Clinical Sleep Medicine, showcasing comprehensive 12-month safety and efficacy results for its Genio® system in treating Obstructive Sleep Apnea (OSA).The study demonstrated strong results with 63.5% AHI responder rate and 71.3% ODI responder rate. Patient engagement was remarkable, with 84.3% of participants using the device more than 4 hours in over 70% of nights, and 90% of patients expressing satisfaction. The device showed a 66.6% median reduction in supine AHI at 12 months.Safety results aligned with other neuromodulation therapies, showing 11 serious adverse events in ten subjects (8.7% SAE rate), with only three being device-related. Quality-of-life outcomes improved significantly, with a 2.3-point increase in FOSQ assessment and 3.4-point reduction in Epworth Sleepiness Score.

#NYXH Nyxoah’s DREAM Pivotal Study Data Published in the Journal of Clinical Sleep Medicine

www.stocktitan.net/news/NYXH/nyxoah-s-dream...

Let's make June the month with the most followers gained on Twitch, we just need to beat March with 48. >:3

www.twitch.tv/nyxthenephalem

#twitch #pridemonth #June #twitchstreamer #follow #follower #Vsky #vtuber #VT #enVT #enVtuber #MTF #trans #transVt #transvtuber #streamer #NyxH #nephalem #goal

Vestal Point Capital Cuts Nyxoah Holdings by 40%: Major Ownership Shift Revealed Investment firm reduces position from 3M to 1.8M shares. Latest transparency filing reveals shifting institutional confidence. See complete ownership details.

#NYXH Publication relating to transparency notifications

www.stocktitan.net/news/NYXH/publication-re...

NyxTheNephalem - Twitch Just a small vtuber who likes working on art and playing random games :3

I'm playing Genshin Impact for the first time :3

96/100 followers

www.twitch.tv/nyxthenephalem

#NoModel #twitch #stream #VT #VTuber #enVT #ps5stream #ps5 #trans #MTF #Genshinimpact #genshin #followergoal #follow #vsky #transVtuber #NyxH

NyxTheNephalem - Twitch Just a small vtuber who likes working on art and playing random games :3

Once again, Marvel Rivals stream, hope to see you there :3

94/100 followers

www.twitch.tv/nyxthenephalem

#NoModel #twitch #stream #VT #VTuber #enVT #ps5stream #ps5 #trans #MTF #Marvel #MarvelRivals #followergoal #follow #vsky #transVtuber #NyxH

Twitch Twitch is the world

Marvel Rivals stream, hope to see you there :3

92/100 followers

www.twitch.tv/nyxthenephalem

#NoModel #twitch #stream #VT #VTuber #enVT #ps5stream #ps5 #trans #MTF #Marvel #MarvelRivals #followergoal #follow #vsky #transVtuber #NyxH

NyxTheNephalem - Twitch Just a small vtuber who likes working on art and playing random games :3

MKXL Stream in about half an hour (~2:30 PM EDT), come by and hang out :3

(Sorry, no model once again, bc I am streaming on the PS5)

also 88/100 followers :3

www.twitch.tv/nyxthenephalem

#goinglive #MKXL #mortalkombat #twitch #Vsky #VT #enVTuber #enVT #trans #streamer #mtf #NyxH #followergoal

Nyxoah Reports First Quarter Financial and Operating Results Nyxoah reported its Q1 2025 financial results and provided an update on its FDA approval progress for the Genio® system, a neuromodulation treatment for Obstructive Sleep Apnea (OSA). The company received an FDA Approvable Letter and successfully completed validation requirements, with only the final site inspection pending. Q1 2025 financial highlights include: - Revenue of €1.1M (down from €1.2M in Q1 2024) - Operating loss increased to €20.6M (vs €12.2M in Q1 2024) - Cash position of €63.0M as of March 31, 2025 - Gross margin of 61.8% The company expects potential FDA approval in Q2 2025, having already completed most regulatory requirements. The increased operating loss reflects higher R&D expenses (€9.0M) and selling, general and administrative costs (€12.4M) as Nyxoah prepares for U.S. commercialization.

#NYXH Nyxoah Reports First Quarter Financial and Operating Results

www.stocktitan.net/news/NYXH/nyxoah-reports...